Real needs

Marketing Authorisations

Amfebutamone/buproprion for smoking cessation: nicotine replacement therapy is safer

Smoking cessation and nicotine replacement therapy

Topical becaplermin: a slight short-term help for some diabetic patients

Oxcarbazepine: an alternative to carbamazepine in partial epilepsy

Partial epilepsy: classifications help little with the therapeutic choice

Zanamivir: still no tangible impact on influenza

Zanamivir has no tangible impact on the spread of influenza: marketing refusal fully justified

Docetaxel: no first-line use in metastatic breast cancer

Chemotherapy and metastatic breast cancer: hormone therapy first

Galantamine: the fourth cholinesterase inhibitor for Alzheimer's disease

Trospium: no advantages over oxybutynin but price is soaring

Mofetil mycophenolate: better outcome after liver grafting

Sevelamer: second-line treatment of hyperphosphoraemia in haemodialysis patients

Eprosartan: hypertension: a me-too angiotensin II antagonist; no advance

Cetrorelix: no better than Gn-RH analogues in ovarian stimulation

Adverse Effects

NSAIDs and heart failure

Thioridazine and severe cardiac arrhythmia

Severe systemic effects with topical fluorouracil

Reviews

Steroid therapy of acute ENT infections: rarely indicated

In vitro fertilisation: many unknowns

Outlook

Safety of paracetamol packaging in the United Kingdom